JP2017527614A - 重水素化又は非重水素化分子及び医薬製剤 - Google Patents

重水素化又は非重水素化分子及び医薬製剤 Download PDF

Info

Publication number
JP2017527614A
JP2017527614A JP2017531457A JP2017531457A JP2017527614A JP 2017527614 A JP2017527614 A JP 2017527614A JP 2017531457 A JP2017531457 A JP 2017531457A JP 2017531457 A JP2017531457 A JP 2017531457A JP 2017527614 A JP2017527614 A JP 2017527614A
Authority
JP
Japan
Prior art keywords
site
tetrahydrocurcumin
deuterated
subject
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017531457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527614A5 (https=
Inventor
ブピンダー シン
ブピンダー シン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2017527614A publication Critical patent/JP2017527614A/ja
Publication of JP2017527614A5 publication Critical patent/JP2017527614A5/ja
Priority to JP2022180359A priority Critical patent/JP2023011921A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/04—Saturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/17—Saturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C07C49/172—Saturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017531457A 2014-09-02 2015-08-31 重水素化又は非重水素化分子及び医薬製剤 Pending JP2017527614A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022180359A JP2023011921A (ja) 2014-09-02 2022-11-10 重水素化又は非重水素化分子及び医薬製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462044566P 2014-09-02 2014-09-02
US62/044,566 2014-09-02
PCT/US2015/047822 WO2016036674A1 (en) 2014-09-02 2015-08-31 Deuterated or a non-deuterated molecule and pharmaceutical formulations

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020153867A Division JP2021001193A (ja) 2014-09-02 2020-09-14 重水素化又は非重水素化分子及び医薬製剤
JP2022180359A Division JP2023011921A (ja) 2014-09-02 2022-11-10 重水素化又は非重水素化分子及び医薬製剤

Publications (2)

Publication Number Publication Date
JP2017527614A true JP2017527614A (ja) 2017-09-21
JP2017527614A5 JP2017527614A5 (https=) 2018-10-11

Family

ID=55401248

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017531457A Pending JP2017527614A (ja) 2014-09-02 2015-08-31 重水素化又は非重水素化分子及び医薬製剤
JP2020153867A Pending JP2021001193A (ja) 2014-09-02 2020-09-14 重水素化又は非重水素化分子及び医薬製剤
JP2022180359A Pending JP2023011921A (ja) 2014-09-02 2022-11-10 重水素化又は非重水素化分子及び医薬製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020153867A Pending JP2021001193A (ja) 2014-09-02 2020-09-14 重水素化又は非重水素化分子及び医薬製剤
JP2022180359A Pending JP2023011921A (ja) 2014-09-02 2022-11-10 重水素化又は非重水素化分子及び医薬製剤

Country Status (9)

Country Link
US (3) US9375408B2 (https=)
EP (2) EP3628640B1 (https=)
JP (3) JP2017527614A (https=)
CN (1) CN106794986A (https=)
AU (4) AU2015312134A1 (https=)
CA (1) CA2959965A1 (https=)
IL (2) IL285760B2 (https=)
MX (2) MX372723B (https=)
WO (1) WO2016036674A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021526221A (ja) * 2018-05-24 2021-09-30 レニバス・セラピューティクス・インコーポレイテッド 腎障害及び腎不全のリスクのある患者を治療する方法
JP2024028798A (ja) * 2019-11-07 2024-03-05 サイビン ユーケー リミテッド 化合物
JP2024513775A (ja) * 2021-03-25 2024-03-27 サミ－サビンサ グループ リミテッド 腎症を管理するための組成物及び方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
EP3628640B1 (en) 2014-09-02 2023-08-09 Hub Therapeutics Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
WO2017218004A1 (en) * 2016-06-17 2017-12-21 Michael Hudnall Medical food for patients with chronic liver disease
MX2019010576A (es) 2017-03-16 2019-10-07 Aldeyra Therapeutics Inc Compuestos polimorficos y usos de los mismos.
US10934241B2 (en) * 2017-06-16 2021-03-02 University Of North Florida Board Of Trustees Curcuminoid-inspired synthetic compounds as anti-tumor agents
US11117907B2 (en) 2017-06-16 2021-09-14 University Of North Florida Board Of Trustees Curcuminoid-inspired synthetic compounds as anti-tumor agents
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス， インコーポレイテッド 炎症性障害の処置
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2020181256A1 (en) * 2019-03-06 2020-09-10 Renibus Therapeutics, Inc. Novel tetrahydrocurcumin compositions, methods of making, and methods of using the same
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3142023A1 (en) * 2019-05-28 2020-12-03 Case Western Reserve University Compositions and methods for preserving dna methylation
CN111017878B (zh) * 2019-12-18 2021-12-17 中国原子能科学研究院 一种用于制备平衡态h2-hd-d2标准气体的装置和方法
WO2021138561A1 (en) * 2019-12-31 2021-07-08 Renibus Therapeutics, Inc. Novel tetrahydrocurcumin compositions, methods of making, and methods of using the same
US11883371B2 (en) * 2020-03-23 2024-01-30 Renibus Therapeutics, Inc. Stress test and treatment of chronic kidney disease
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof
AU2021281223A1 (en) 2020-05-27 2023-01-05 Case Western Reserve University Compositions and methods for preserving DNA methylation
CN111759820B (zh) * 2020-08-24 2022-04-19 武汉人福药业有限责任公司 一种奥卡西平片剂及其制备方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11246398A (ja) * 1998-03-02 1999-09-14 Kyowa Hakko Kogyo Co Ltd 生体内過酸化脂質増加に起因する疾患の予防または治療剤
JP2006512943A (ja) * 2002-11-20 2006-04-20 アイソテクニカ， インターナショナル インコーポレイテッド 重水素化ラパマイシンの制御された送達のための、重水素化ラパマイシンを組み込む医療用デバイス
JP2007517909A (ja) * 2004-01-14 2007-07-05 ギリアード サイエンシーズ， インコーポレイテッド 薬物送達に有用な脂質ベースの分散物
JP2007320864A (ja) * 2006-05-30 2007-12-13 Toshihiko Osawa 非アルコール性脂肪肝炎予防・治療用組成物
JP2008133272A (ja) * 2006-10-31 2008-06-12 Ito En Ltd Ｃｐｔ活性亢進剤及び飲食物
WO2008093848A1 (ja) * 2007-02-02 2008-08-07 Sunstar Inc. ホスファチジルコリンを含有する炎症マーカー低減組成物
JP2008201768A (ja) * 2006-11-24 2008-09-04 Mizu Kk 抗炎症剤及びシクロオキシゲナーゼ阻害剤
JP2009502872A (ja) * 2005-07-26 2009-01-29 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 同位体置換されたパントプラゾール
JP2009511481A (ja) * 2005-10-06 2009-03-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 増強された治療特性を持つ、胃Ｈ＋，Ｋ＋−ＡＴＰａｓｅの重水素化阻害剤
CN101627969A (zh) * 2009-07-30 2010-01-20 浙江工业大学 一种新型的姜黄素自乳化给药系统及其制备
CN101732292A (zh) * 2010-01-25 2010-06-16 四川省中医药科学院 四氢姜黄素的新用途
JP2010260816A (ja) * 2009-05-07 2010-11-18 Theravalues Corp ウコン色素組成物による心機能改善効果

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5276182A (en) 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers
DE4039602A1 (de) 1990-12-12 1992-06-17 Bauer Kurt Heinz Prof Dr Pharmazeutische formulierungen
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5683676A (en) 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
ES2224200T3 (es) 1992-11-27 2005-03-01 Mayne Pharma (Usa) Inc. Composicion inyectable estable de paclitaxel.
US5654286A (en) 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
CZ301771B6 (cs) 1993-10-01 2010-06-16 Syntex (U.S.A.) Llc. Farmaceutický prostredek ve forme suchého granulátu obsahující mofetil mykofenolát nebo kyselinu mykofenolovou a zpusob jeho prípravy
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US6342507B1 (en) * 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
US7442720B2 (en) * 2003-12-19 2008-10-28 Omega Bio-Pharma (I.P.3) Limited Compositions and methods for treating diabetes
US8841326B2 (en) * 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
CN1283237C (zh) 2004-11-22 2006-11-08 山东大学 姜黄素磷脂复合物及其制备方法
US7776915B2 (en) 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
WO2010097643A1 (en) * 2009-02-24 2010-09-02 Novatech Istrazivanje D.O.O. Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite
WO2011047309A2 (en) * 2009-10-16 2011-04-21 The Research Foundation Of State University Of New York Treatment of ischemic tissue
CN102526003B (zh) * 2010-01-25 2014-02-19 四川省中医药科学院 四氢姜黄素的用途
WO2011116066A1 (en) * 2010-03-17 2011-09-22 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
WO2013033250A1 (en) * 2011-09-01 2013-03-07 Xiangping Qian Certain chemical entities, compositions, and methods
CN104739813A (zh) * 2013-12-26 2015-07-01 四川省中医药科学院 四氢姜黄素的新用途
EP3628640B1 (en) * 2014-09-02 2023-08-09 Hub Therapeutics Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11246398A (ja) * 1998-03-02 1999-09-14 Kyowa Hakko Kogyo Co Ltd 生体内過酸化脂質増加に起因する疾患の予防または治療剤
JP2006512943A (ja) * 2002-11-20 2006-04-20 アイソテクニカ， インターナショナル インコーポレイテッド 重水素化ラパマイシンの制御された送達のための、重水素化ラパマイシンを組み込む医療用デバイス
JP2007517909A (ja) * 2004-01-14 2007-07-05 ギリアード サイエンシーズ， インコーポレイテッド 薬物送達に有用な脂質ベースの分散物
JP2009502872A (ja) * 2005-07-26 2009-01-29 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 同位体置換されたパントプラゾール
JP2009511481A (ja) * 2005-10-06 2009-03-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 増強された治療特性を持つ、胃Ｈ＋，Ｋ＋−ＡＴＰａｓｅの重水素化阻害剤
JP2007320864A (ja) * 2006-05-30 2007-12-13 Toshihiko Osawa 非アルコール性脂肪肝炎予防・治療用組成物
JP2008133272A (ja) * 2006-10-31 2008-06-12 Ito En Ltd Ｃｐｔ活性亢進剤及び飲食物
JP2008201768A (ja) * 2006-11-24 2008-09-04 Mizu Kk 抗炎症剤及びシクロオキシゲナーゼ阻害剤
WO2008093848A1 (ja) * 2007-02-02 2008-08-07 Sunstar Inc. ホスファチジルコリンを含有する炎症マーカー低減組成物
JP2010260816A (ja) * 2009-05-07 2010-11-18 Theravalues Corp ウコン色素組成物による心機能改善効果
CN101627969A (zh) * 2009-07-30 2010-01-20 浙江工业大学 一种新型的姜黄素自乳化给药系统及其制备
CN101732292A (zh) * 2010-01-25 2010-06-16 四川省中医药科学院 四氢姜黄素的新用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AAPS PHARMSCITECH, vol. 12, no. 1, JPN6019025333, 2011, pages 152 - 164, ISSN: 0004385304 *
BIOCHEMICAL PHARMACOLOGY, vol. 75, JPN6019025337, 2008, pages 787 - 809, ISSN: 0004069716 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021526221A (ja) * 2018-05-24 2021-09-30 レニバス・セラピューティクス・インコーポレイテッド 腎障害及び腎不全のリスクのある患者を治療する方法
US11965896B2 (en) 2018-05-24 2024-04-23 Renibus Therapeutics, Inc. Methods of treating patients at risk for renal injury and renal failure
JP2024028798A (ja) * 2019-11-07 2024-03-05 サイビン ユーケー リミテッド 化合物
JP7748437B2 (ja) 2019-11-07 2025-10-02 サイビン ユーケー リミテッド 化合物
JP2024513775A (ja) * 2021-03-25 2024-03-27 サミ－サビンサ グループ リミテッド 腎症を管理するための組成物及び方法

Also Published As

Publication number Publication date
AU2019250097A1 (en) 2019-10-31
IL285760A (en) 2021-09-30
MX2020005446A (es) 2020-08-27
EP3189007B1 (en) 2019-10-02
JP2021001193A (ja) 2021-01-07
MX372723B (es) 2020-06-19
AU2023274063A1 (en) 2023-12-14
WO2016036674A1 (en) 2016-03-10
IL250861A0 (en) 2017-04-30
US20200377441A1 (en) 2020-12-03
EP3628640A1 (en) 2020-04-01
IL285760B2 (en) 2025-03-01
CN106794986A (zh) 2017-05-31
US9375408B2 (en) 2016-06-28
CA2959965A1 (en) 2016-03-10
EP3189007A4 (en) 2018-05-16
US20160058713A1 (en) 2016-03-03
AU2015312134A1 (en) 2017-03-23
IL285760B1 (en) 2024-11-01
US10781158B2 (en) 2020-09-22
IL250861B (en) 2021-09-30
US20170029354A1 (en) 2017-02-02
EP3189007A1 (en) 2017-07-12
JP2023011921A (ja) 2023-01-24
EP3628640B1 (en) 2023-08-09
AU2021236495A1 (en) 2021-10-21
MX2017002750A (es) 2017-08-02

Similar Documents

Publication Publication Date Title
US20200377441A1 (en) Methods of protecting an organ using tetrahydrocurcumin and phosphatidylcholine
JP2017214413A (ja) エピメタボリックシフター、多次元細胞内分子、または環境影響因子を使用する代謝性障害の治療方法
WO2007113748A1 (en) Oral formulation with beneficial cardiovascular effects, comprising berberine
CN106604725A (zh) 治疗肥胖症，防止体重增加，促进体重减轻，促进减肥，或治疗或预防糖尿病的发展的方法和组合物
WO2006034463A2 (en) Herbal supplement to support weight loss
Jihwaprani et al. Pharmacokinetics of quercetin
EP1800674A1 (en) Agent for preventing metabolic syndrome
TWI359667B (en) Formulation for oral administration having a healt
HK40026907B (en) Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
HK40026907A (en) Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
KR20100060949A (ko) 신경세포 보호용 조성물
EP4262429A1 (en) Compositions for targeting receptor for advanced glycation end-products (rage) in a chronic inflammatory condition
EP3466433B1 (en) Triacetyl-3-hydroxyl phenyl adenosine for use in treating acute vascular inflammations
US20080161413A1 (en) Agent for increasing adiponectin in blood
US10881686B2 (en) Compositions and methods for treating and preventing proteinuria and endothelial erosion
KR20260059471A (ko) 내당능 장애 및 당뇨병성 신장병의 예방 또는 치료용 조성물
EP3446689B1 (en) Isothiocyanate compound for use in the treatment of hyperbilirubinemia
JPH0371412B2 (https=)
JP2024529643A (ja) スルフォラファンとグリシンとを含む混合物及び組成物
JP2012232918A (ja) 血糖値低下剤
HK1262703B (en) Triacetyl-3-hydroxyl phenyl adenosine for use in treating acute vascular inflammations
HK1262703A1 (en) Triacetyl-3-hydroxyl phenyl adenosine for use in treating acute vascular inflammations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200914

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200914

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200924

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200929

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20201113

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20201117

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210413

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210615

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210629

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20210629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211224

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220809

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20221213

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20230110

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20230110